Richard Chesworth

6.7k citations

32 papers · 2.4k indexed · 2 hit papers · h-index 17

Molecular Biology top 5%
- Cancer-related gene regulation 17
- Epigenetics and DNA Methylation 16
- Chromatin Remodeling and Cancer 3
- Protein Degradation and Inhibitors 3
- RNA modifications and cancer 3
Hematology top 5%
- Acute Myeloid Leukemia Research 3
Pathology and Forensic Medicine top 10%
- Cancer Mechanisms and Therapy 2
Sensory Systems top 10%
Cancer Research
Pharmacology
- Cholinesterase and Neurodegenerative Diseases 3

Co-authors: Robert A. Copeland Mikel P. Moyer Roy M. Pollock Margaret Porter Scott Victoria M. Richon Christina J. Allain Alejandra Raimondi Christine R. Klaus
Cited by: Molecular Biology Hematology Pathology and Forensic Medicine
Journals: Proceedings of the National Academy of Sciences (1 paper)Journal of the American Chemical Society (1 paper)Blood (4 papers)
Partner nations: United States United Kingdom Japan

In The Last Decade

Richard Chesworth

30 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Richard Chesworth

Since Specialization

Citations

This map shows the geographic impact of Richard Chesworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Chesworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Chesworth more than expected).

Fields of papers citing papers by Richard Chesworth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Chesworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Chesworth. The network helps show where Richard Chesworth may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Richard Chesworth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Richard Chesworth Line = papers co-authored together Richard Chesworth links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Identification of a peptide inhibitor for the histone methyltransferase WHSC1 PLoS ONE ·Michael J. Morrison,P. Ann Boriack‐Sjodin,Kerren K. Swinger,Tim J. Wigle,Dipti Sadalge,Kevin W. Kuntz,Margaret Porter Scott,William P. Janzen,Richard Chesworth,Kenneth W. Duncan,Darren M. Harvey,John W. Lampe,Lorna H. Mitchell,Robert A. Copeland	2018	22
2	Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models Molecular Cancer Therapeutics ·Elayne Chan-Penebre,Kelli Armstrong,Allison E. Drew,Alexandra Grassian,Igor Feldman,Sarah K. Knutson,Kristy Kuplast‐Barr,Maria Roche,John Campbell,Peter Ho,Robert A. Copeland,Richard Chesworth,J. Joshua Smith,Heike Keilhack,Scott Ribich	2017	127
3	Abstract 5060: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models Cancer Research ·Allison E. Drew,Vinny Motwani,John E. Campbell,Cuyue Tang,J. Joshua Smith,Richard Chesworth,Robert A. Copeland,Alejandra Raimondi,Scott Ribich	2017	3
4	Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human Cancer Chemotherapy and Pharmacology ·Nigel J. Waters,Sherri Smith,Edward J. Olhava,Kenneth W. Duncan,Richard D. E. Burton,James O’Neill,Marie-Ève Rodrigue,Roy M. Pollock,Mikel P. Moyer,Richard Chesworth	2015	23
5	A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening SLAS DISCOVERY ·Tim J. Wigle,Kerren K. Swinger,John E. Campbell,Michael D. Scholle,John Sherrill,Elizabeth A. Admirand,P. Ann Boriack‐Sjodin,Kevin W. Kuntz,Richard Chesworth,Mikel P. Moyer,Margaret Porter Scott,Robert A. Copeland	2015	31
6	Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652 Drug Metabolism and Disposition ·Nathalie Rioux,Lorna H. Mitchell,Philip R. Tiller,Katie Plant,J.P. Shaw,Kerry Frost,Scott Ribich,Mikel P. Moyer,Robert A. Copeland,Richard Chesworth,Nigel J. Waters	2015	5
7	Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor Xenobiotica ·Nathalie Rioux,Kenneth W. Duncan,Ronald J. Lantz,Xiu‐Sheng Miao,Elayne Chan-Penebre,Mikel P. Moyer,Michael J. Munchhof,Robert A. Copeland,Richard Chesworth,Nigel J. Waters	2015	16
8	Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound ACS Medicinal Chemistry Letters ·Lorna H. Mitchell,Allison E. Drew,Scott Ribich,Nathalie Rioux,Kerren K. Swinger,Suzanne L. Jacques,Trupti Lingaraj,P. Ann Boriack‐Sjodin,Nigel J. Waters,Tim J. Wigle,Oscar Moradei,Lei Jin,Thomas V. Riera,Margaret Porter-Scott,Mikel P. Moyer,J. Joshua Smith,Richard Chesworth,Robert A. Copeland	2015	95
9	Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666 ACS Medicinal Chemistry Letters ·Kenneth W. Duncan,Nathalie Rioux,P. Ann Boriack‐Sjodin,Michael J. Munchhof,Lawrence A. Reiter,Christina R. Majer,Lei Jin,L. Danielle Johnston,Elayne Chan-Penebre,Kristy G. Kuplast,Margaret Porter Scott,Roy M. Pollock,Nigel J. Waters,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Richard Chesworth	2015	103
10	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity ACS Medicinal Chemistry Letters ·John E. Campbell,Kevin W. Kuntz,Sarah K. Knutson,Natalie M. Warholic,Heike Keilhack,Tim J. Wigle,Alejandra Raimondi,Christine R. Klaus,Nathalie Rioux,Akira Yokoi,Satoshi Kawano,Yukinori Minoshima,Hyeong-Wook Choi,Margaret Porter Scott,Nigel J. Waters,J. Joshua Smith,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland	2015	94
11	Abstract A135: Physiologically-based pharmacokinetic modeling to support clinical investigation of the EZH2 inhibitor, tazemetostat (EPZ-6438) in INI1-deficient pediatric tumors Molecular Cancer Therapeutics ·Nathalie Rioux,Heike Keilhack,Blythe Thomson,Richard Chesworth,Robert A. Copeland,Eric Hedrick,Peter Ho,Nigel J. Waters	2015	2
12	Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor Biopharmaceutics & Drug Disposition ·Aravind Basavapathruni,Edward J. Olhava,Scott R. Daigle,Carly A. Therkelsen,Lei Jin,P. Ann Boriack‐Sjodin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Angelos Dovletoglou,Victoria M. Richon,Roy M. Pollock,Robert A. Copeland,Mikel P. Moyer,Richard Chesworth,Paul G. Pearson,Nigel J. Waters	2014	64
13	Potent inhibition of DOT1L as treatment of MLL-fusion leukemiabreakdown → Blood ·Scott R. Daigle,Edward J. Olhava,Carly A. Therkelsen,Aravind Basavapathruni,Lei Jin,P. Ann Boriack‐Sjodin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Nigel J. Waters,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Roy M. Pollock	2013	546
14	Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L Chemical Biology & Drug Design ·Aravind Basavapathruni,Lei Jin,Scott R. Daigle,Christina R. Majer,Carly A. Therkelsen,Tim J. Wigle,Kevin W. Kuntz,Richard Chesworth,Roy M. Pollock,Margaret Porter Scott,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Edward J. Olhava	2012	114
15	Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia. Blood ·Roy M. Pollock,Scott R. Daigle,Carly A. Therkelsen,Aravind Basavapathruni,Lei Jin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Edward J. Olhava	2012	3
16	EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors Neuropharmacology ·Jos Prickaerts,Nick P. van Goethem,Richard Chesworth,Gideon Shapiro,Frank Boess,Christoph Methfessel,Olga A.H. Reneerkens,Dorothy G. Flood,Dana Hilt,Maria S. Gawryl,Sonia Bertrand,Daniel Bertrand,Gerhard König	2011	174
17	Neuronal Store-Operated Calcium Entry Pathway as a Novel Therapeutic Target for Huntington's Disease Treatment Chemistry & Biology ·Jun Wu,Hsin-Pei Shih,V. A. Vigont,Lori Hrdlicka,Len Diggins,Carol M. Singh,Matt B. Mahoney,Richard Chesworth,Gideon Shapiro,O. A. Zimina,Xuesong Chen,Qingqing Wu,Л. Н. Глушанкова,Michael K. Ahlijanian,Gerhard Koenig,G. N. Mozhayeva,Еlena Kaznacheyeva,Ilya Bezprozvanny	2011	127
18	P3‐295: Pharmacokinetic and pharmacodynamic analysis of the gamma‐secretase modulator (GSM) EVP‐0015962 Alzheimer s & Dementia ·Kevin M. Felsenstein,Darcie Spaulding,Zhiyong Yang,Hilliary Hodgdon,Don Costa,Scott Nolan,Melody Wen,Winnie Lee,Lori Hrdlicka,Florentina Catana,Faris Albayya,Zhiming Tu,Holger Patzke,Richard Chesworth,Gideon Shapiro,Irena Zaninovic,Michael K. Ahlijanian,Gerhard Koenig,Kathryn Rogers	2010	4
19	Discovery and Development of Novel HDAC Inhibitors for Huntington’s Disease Neurotherapeutics ·Holger Patzke,Richard Chesworth,Zhe Li,G. Rahil,J WANG,Jessica Smith,F. Huet,Gideon Shapiro,S. Leit,Pierre Beaulieu,F. Raeppel,Mélanie Fournel,H. Sainte-Croix,Sarah J Nevitt,F.P. Albayya,Anne Barbier,J. Besterman,Michael K. Ahlijanian,R. Deziel	2008	1
20	Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists Bioorganic & Medicinal Chemistry Letters ·Richard Chesworth,Michael P. Zawistoski,Bruce A. Lefker,Kimberly O. Cameron,Robert F. Day,F. Michael Mangano,Robert L. Rosati,Stacy Colella,Donna N. Petersen,Amy Brault,Bihong Lu,Lydia C. Pan,Pia Perry,Oicheng Ng,Tessa A. Castleberry,Thomas A. Owen,Thomas A. Brown,David D. Thompson,Paul DaSilva‐Jardine	2004	32

About Richard Chesworth

Richard Chesworth is a scholar working on Molecular Biology, Hematology and Toxicology, having authored 32 papers that have together received 2.4k indexed citations. Recurring topics across this work include Cancer-related gene regulation (17 papers), Epigenetics and DNA Methylation (16 papers), Acute Myeloid Leukemia Research (3 papers), Cholinesterase and Neurodegenerative Diseases (3 papers), Chromatin Remodeling and Cancer (3 papers), Protein Degradation and Inhibitors (3 papers), RNA modifications and cancer (3 papers) and Cancer Mechanisms and Therapy (2 papers). The work is most often cited by research in Molecular Biology (2.1k citations), Hematology (223 citations) and Pathology and Forensic Medicine (192 citations). Richard Chesworth has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Robert A. Copeland, Mikel P. Moyer, Roy M. Pollock, Margaret Porter Scott, Victoria M. Richon, Christina J. Allain, Alejandra Raimondi, Christine R. Klaus, Tim J. Wigle and Kevin W. Kuntz. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact